Use of recombinant human interferon alpha-2a in the management of a dog with epitheliotropic lymphoma.
An 8-year-old, mixed-breed dog with preputial epitheliotropic lymphoma was initially treated with cyclophosphamide, vincristine, and prednisolone. A short-term partial response was followed by disease progression after 4 weeks. Recombinant human interferon alpha-2a was administered starting at week 7. The interferon therapy resulted in rapid resolution of clinical signs and a 10-week disease-free interval. The lymphoma recurred at 17 weeks and did not respond to rescue chemotherapy. Additional oral lesions were treated with localized radiotherapy followed by increased dosages of interferon. This additional interferon treatment resulted in another 12 weeks of stable disease.
Tzannes
Sophia
S
Department of Clinical Veterinary Science, Small Animal Teaching Hospital, University of Liverpool, Leahurst, Chester High Road, Neston, Cheshire, CH647TE, United Kingdom.
Ibarrola
Patricia
P
Batchelor
Daniel J
DJ
Burrow
Rachel D
RD
Blackwood
Laura
L